Uric acid and the prediction models of tumor lysis syndrome in AML
about
Considering renal risk while managing cancer.Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.Serum uric acid and acute kidney injury: A mini review.Tumor Lysis Syndrome in Patients with Hematological Malignancies.
P2860
Uric acid and the prediction models of tumor lysis syndrome in AML
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Uric acid and the prediction models of tumor lysis syndrome in AML
@ast
Uric acid and the prediction models of tumor lysis syndrome in AML
@en
type
label
Uric acid and the prediction models of tumor lysis syndrome in AML
@ast
Uric acid and the prediction models of tumor lysis syndrome in AML
@en
prefLabel
Uric acid and the prediction models of tumor lysis syndrome in AML
@ast
Uric acid and the prediction models of tumor lysis syndrome in AML
@en
P2093
P2860
P1433
P1476
Uric acid and the prediction models of tumor lysis syndrome in AML
@en
P2093
A Ahsan Ejaz
Bryan A Smallwood
Jack W Hsu
Negiin Pourafshar
Richard J Johnson
P2860
P304
P356
10.1371/JOURNAL.PONE.0119497
P407
P577
2015-03-16T00:00:00Z